Feasibility study of an optimised person-centred intervention to improve mental health and reduce antipsychotics amongst people with dementia in care homes: study protocol for a randomised controlled trial by Whitaker, R et al.
STUDY PROTOCOL Open Access
Feasibility study of an optimised person-centred
intervention to improve mental health and
reduce antipsychotics amongst people with
dementia in care homes: study protocol for a
randomised controlled trial
Rhiannon Whitaker
1, Clive Ballard
2, Jane Stafford
3*, Martin Orrell
4, Esme Moniz-Cook
5, Robert T Woods
6,
Joanna Murray
7, Martin Knapp
8, Barbara Woodward Carlton
9 and Jane Fossey
3
Abstract
Background: People living in care homes often have complex mental and physical health problems, disabilities
and social needs which are compounded by the use of psychiatric and other drugs. In the UK dementia care is a
national priority with a vast impact on services. WHELD combines the most effective elements of existing
approaches to develop a comprehensive but practical intervention. This will be achieved by training care staff to
provide care that is focused on an understanding of the individual and their needs; and by using additional
components such as exercise, activities and social interaction to improve mental health and quality of life (QoL) and
reduce the use of sedative drugs.
Design: Work Package 3 (WP3) is the pilot randomised trial and qualitative evaluation to help develop a future
definitive randomised controlled clinical trial. The study design is a cluster randomised 2x2x2 factorial design with
two replications in 16 care homes. Each care home is randomized to receive one of the eight possible
permutations of the four key interventions, with each possible combination delivered in two of the 16 homes. Each
cluster includes a minimum of 12 participants (depending upon size of the care home, the number of people with
dementia and the number consenting).
Discussion: The overarching goal of the programme is to provide an effective, simple and practical intervention
which improves the mental health of, and reduces sedative drug use in, people with dementia in care homes and
which can be implemented nationally in all UK care homes as an NHS intervention.
Trial Registration: Current controlled trials ISRCTN40313497
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Twenty five million people worldwide have dementia, in-
cluding 700,000 in the UK [1], of whom an estimated
250,000 live in care homes [1,2]. Older people with demen-
tia in care homes have complex needs; for example,
cognitive and functional impairment often coexists with
additional mental health problems such as aggression,
agitation, depression and psychosis [3]. These difficulties
are further compounded by the widespread prescription of
antipsychotic drugs [2,4]. The cost of prescription of anti-
psychotic medication is estimated to be £84 million a year
for 140,000 people in the UK, who are unlikely to benefit
and may be harmed by them [5].
Dementia has a vast impact on Health and Social Care
Services. The direct cost of Alzheimer’s disease is £17
billion per year [1], greater than for stroke, heart disease
and cancer combined. The high level of unmet need and
the management of key health and mental health issues are
matters for serious concern both nationally [6], and inter-
nationally [7]. In the UK this led to the National Dementia
Strategy (NDS) [8], which was developed as a partnership
between the Department of Health (DH) and key stake-
holders such as the Alzheimer’sS o c i e t y .I ti sau n i q u e
vision for people with dementia and provides a five-year
plan to ‘develop services for people with dementia and their
carers that are fit for the 21st century and that meet the
needs of everyone’. Key goals include objective number 11
‘Improving the quality of care for people with dementia in
care homes’ , achieved through a variety of measures, includ-
ing visits from specialist mental health teams, and objective
13, the development of an ‘informed and effective work-
force for people with dementia’ , whereby health and social
care staff will receive the right training and have the right
skills to deliver the best care.
The National Service Framework (NSF) for older people
[9], the National Institute for Clinical Excellence (NICE)
dementia guidelines [10] and a market analysis [11,12] also
h i g h l i g h tt h ei m p o r t a n c eo ft r a ining for care staff and the
need to improve access to effective non-pharmacological
therapies. The DH has also conducted a review of anti-
psychotic prescribing [13,14] for people with dementia,
which recommends a substantial reduction in unnecessary
prescribing. This adds further weight to the recommenda-
tions of the NDS, the NSF and the NICE dementia guide-
lines to improve the treatment and care for people with
dementia in care homes. Care home regulators in the US
have launched initiatives to tackle the same key issues [15].
The NDS vision of enabling people with dementia in care
homes to live well with dementia needs to be underpinned
by effective, evidence-based interventions that are standar-
dized, consistent, practical and can be delivered as part of
the National Health Service (NHS).
Improving the care of mental health problems, redu-
cing antipsychotic use and improving quality of life for
people with dementia in care homes are all key NHS
priorities. There is strong evidence that staff training,
promoting person-centred care (PCC) and utilising non-
pharmacological interventions improve some key health
outcomes and can reduce antipsychotic drug use [10,16].
However, the breadth of benefit conferred by most of
these interventions is modest; none have directly
improved the quality of life (QoL) for care home resi-
dents with dementia, and importantly, none have
achieved widespread implementation in a health or care
setting as part of routine NHS practice.
Further research is therefore urgently needed to address
these key issues. There is a need for an optimised therapy
combining the most effective elements of currently avail-
able evidence-based interventions that are conceptually
integrated, cost-effective and practical to implement in a
range of settings. To achieve these objectives there is a need
to evaluate the key components of effective interventions to
enable the development of an optimised intervention.
Overcoming the barriers to implementation, which is rare
in dementia care research and has never been achieved for
a n yt h e r a p yi nac a r eh o m es e t t i n g ,i sa l s oam a j o rc h a l -
lenge. Research is needed to tailor an optimised therapy to
the needs of mental health practitioners, care home staff
and people with dementia in care homes. In addition,
research should identify and overcome the potential obsta-
cles to implementation, and refine the intervention model
through in-depth field testing. This programme aims to
provide an effective, simple and practical intervention that
improves mental health and reduces sedative drug use for
people with dementia in care homes, and which is replic-
able and scalable to enable it to be widely used in the UK
and internationally. The current paper describes the pilot
study and qualitative evaluation, setting the foundation for
the full-scale multicentre randomised controlled clinical
trial to evaluate an optimised intervention ‘welding to-
gether’ the most effective elements of the best currently
available intervention programmes and a standardised
manual and training programme (WHELD).
Study objectives
The pilot study follows a factorial randomised controlled
clinical trial design. Evaluations will be undertaken to
understand the breadth of additional benefits conferred by
three interventions, namely, antipsychotic review (discon-
tinuation and safety); social interaction and pleasant activ-
ities; and exercise, compared with PCC alone.
Hypotheses
Each intervention will significantly improve several key out-
comes but none when used alone will improve all out-
comes. This pilot randomised trial is not powered to
provide a definitive answer but to guide the analysis and to
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scale cluster randomised trial.
Specifically the hypotheses are that compared to person-
centred care alone are:
1. PCC plus antipsychotic review will result in the
reduction of antipsychotic prescribing.
2. PCC and social interaction with pleasant activities
will result in reductions in agitation/aggression,
especially in individuals already experiencing these
symptoms at the baseline evaluation.
3. PCC and exercise will improve mood and reduce falls.
Secondary objectives and qualitative evaluation
To inform subsequent work, the key secondary objectives
are to determine the specific impact of each therapy on a
range of outcomes including, mental health, psychotropic
drug use, physical health and QoL, as well as the impact on
potentially important mediating factors such as activities,
social interaction, staff attitudes and the quality of the inter-
action between care staff and people with dementia.
The purpose of the qualitative research is to develop
understanding of the process of implementation within
the care environment. Staff beliefs, attitudes and behav-
iour in their work with people with dementia are key
components. Recognition and acknowledgement of staff
perspectives is also essential to negotiating the imple-
mentation of the interventions.
Methods/Design
Overall design
The study design is a cluster-randomised, 2×2×2 factorial
design (with two replications), pilot study in 16 care homes,
as shown in Figure 1. Each cluster includes a minimum of
12 participants (depending upon the size of the care home,
the number of people with dementia and the number con-
senting). Each cluster receives a randomly allocated inter-
vention for a minimum of nine months. Evaluations will be
undertaken to understand the breadth of benefits conferred
by three key interventions to be assessed when used in
addition to the person-centred care training package, where
efficacy has already been established. The flow chart for the
r e s e a r c hi ss h o w ni nF i g u r e2 .
The WHELD PCC intervention primarily uses the tools
developed in evidence-based approaches for improving care
in care homes in the operationalized Focussed Intervention,
Training and Support (FITS) manual [17], which has
demonstrated efficacy in a robust randomised controlled
trial (RCT) [18]. Additional supplementary materials have
been drawn from the best available training manuals from a
robust review of available materials conducted as part of
the WHELD study, and augmented by elements of leader-
ship training on the basis of input from an expert therapy
development group. The intervention has 5 focii:
1. Embedding an understanding of dementia and PCC.
2. Assessing how home practices deliver PCC.
3. Understanding the relationship between an
individuals’ experience and individuals’ behaviour and
well being.
4. Recognising the impact of staff-resident interactions
on the care experience.
5. Implementing PCC planning based on these
principles.
This training package will be delivered to all staff in
the participating care homes.
Antipsychotic review will involve specific review of
antipsychotic drugs by participants’ own General Practi-
tioners (GPs) or psychiatry specialists, based upon the
principles outlined in the NICE dementia guidelines,
and facilitated by an antipsychotic care pathway devel-
oped by the Alzheimer’s Society in partnership with the
DH [13]. GPs will be offered an initial seminar outlining
the best practice guidelines, and prompted when
12-week antipsychotic reviews are due according to
NICE/Social Care Institute for Excellence (SCIE) guide-
lines. Care home staff will be offered a seminar on safe
prescribing, monitoring and review of antipsychotic
drugs. In addition, for all participants continuing to re-
ceive antipsychotic drugs after the initial review, or
where antipsychotic drugs are started or re-started, a
detailed medical antipsychotic care plan will be advised,
using the principles outlined in the antipsychotic care
pathway. This will include planned dates for further
antipsychotic review.
For social interaction with pleasant activities, an in-
tervention manual will be developed based upon three
evidence-based approaches and specific communication
skills training to enhance staff-resident interactions: (1) the
positive events schedule, shown to be effective in the treat-
ment of agitation and depression in people with dementia
in non-care home settings [19,20]; (2) the social interaction
intervention developed by Cohen-Mansfield and colleagues
[21], which is useful for reducing agitation in people with
dementia in care homes; and (3) the Needs, Environment,
Stimulation, and Technique (NEST) programme, devel-
oped by Buettner and colleagues [22], which has been
shown to be effective in improving cognitive function and
reducing agitation and depression. Minor adaptations will
be undertaken, in collaboration with the authors who
developed the manuals, to ensure that they are suitable and
practical for administration in UK care homes.
For exercise, the main focus will be to promote exercise
through encouraging enjoyable positive physical activities.
Teri and colleagues have developed an effective approach,
based on their positive event schedule but focused on
exercise-based activities [20]. The NEST manual [22] and
the Range of Motion (ROM) dance programme [23], which
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arthritis in care settings [24], will be used as specific
resources to offer people enjoyable individual and group ex-
ercise activities to augment activities identified as hobbies
or enjoyable activities by individual participants.
The factorial design is shown below. For example,
care homes 1 and 9 will receive PCC only, while
care home 4 will receive social interaction and exer-
cise in addition to PCC and care home 13 will only
receive antipsychotic review in addition to PCC. Staff
will receive training in the interventions allocated to
the care home, with all care homes receiving training
in the PCC intervention.
Each intervention is delivered by two trained therapists,
who have received an intensive 10-day training package
and who will coordinate the delivery of the intervention
into eight care homes. In each care home two lead
members of the care staff (WHELD champions) will be
trained to implement the intervention.
Number of participants and power of the study
Sixteen suitable care homes to be identified, recruited and
randomised, with the intervention delivered to all residents,
with a minimum recruitment target of 12 individuals with
dementia per care home. All residents within the care
homes, who meet the study’s eligibility criteria will be
invited to participate, which will help to account for the po-
tential loss of participants during the course of the study.
Baseline and follow up data will be collected on all consent-
ing residents who meet the inclusion criteria at each par-
ticipating care home. This is an exploratory pilot study
whose main purpose is to collect data to enable the design
and sample size calculation for the definitive RCT. As such,
Convenience sample 
of care homes 
N approached 
N excluded 
X consented 
Reasons for non 
participation 
List sample of care 
homes 
N approached 
N excluded 
X consented 
Reasons for non 
participation 
Convenience     List        Intervention Allocation 
Sample       Sample     
Block 1    Block 2 
    1              9          PCC 
    2              10        PCC      Ex 
    3              11        PCC    SI   
    4               12        PCC    SI  Ex 
    5              13        PCC  AR   
    6              14        PCC  AR    Ex 
    7              15       PCC  AR  SI   
    8              16        PCC  AR  SI  Ex 
Randomise
s t n a p i c i t r a p l a u d i v i d n i f o r e b m u N
Care 
Homes 
In home  Eligible  Consented Completed 
Intervention
Followed up 
1&9          
2&10          
3&11          
4&12          
5&13          
6&14          
7&15          
8&16          
Intervention 
Figure 1 Design and consort diagram.
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intra-class correlations (ICCs) are unknown.
Randomisation
A restricted randomisation method will allocate the eight
interventions to the eight care homes in the two samples.
The randomisation will be performed as a constrained
complete list randomisation, meaning that all care homes
will have been recruited before the randomisation is
performed. The constraint ensures an approximately equal
distribution of the number of interventions to each
geographic location. The randomisation system used has
been coded and validated in R (statistical package). The R
Foundation for Statistical Computing c/o Institute for
Statistics and Mathematics, Vienna, Austria.
Qualitative evaluation
The qualitative research will increase the understanding
of the process of implementation within the environ-
ment in which the interventions take place. Focus
groups (FGs) have been chosen to investigate the per-
spectives of care staff within the setting in which the
interventions will be tested. The aim of FGs is to
encourage the type of interaction that would occur in
everyday life but with greater focus, and to allow the
researchers access to ideologies, practices and desires
among specific groups of people. Engaging groups of
care staff in discussion of their current work and new
therapeutic approaches is also likely to increase their
collaboration in the research programme. Staff beliefs,
attitudes and behaviour in their work with people with
dementia are key components of this context. Recogni-
tion and acknowledgement of staff perspectives is also
essential to negotiating the implementation of the
interventions.
The first phase of the qualitative evaluation will be
undertaken in the care homes (residential and nursing
homes) participating in the intervention study, prior to
the commencement of the intervention. The pre-
intervention groups at the sixteen participating care
homes will consist of eight to twelve members of the
care staff, including the two lead members of the care
staff who are to be trained to assist with the implemen-
tation of the intervention. Evidence from the systematic
review will provide the initial themes to be explored in
the FGs. Potential issues may, for example, include staff
time to implement interventions and management sup-
port. The topic guide will be revised iteratively to
Identification of potential participant homes from a) prior working 
and b) random selection from the CQC register 
Screening of homes against eligibility criteria, confirm willingness 
to participate 
Identification and recruitment screening of potential participants 
Consents obtained for residents and staff to participate 
Study set-up, database writing, ethics and staff recruitment 
Training of staff 
for interventions 
Randomisation 
Focus groups for staff 
in intervention homes 
Delivery of interventions 
Follow-up assessments at 
9 months from start of 
delivery of interventions
Data cleaning, analysis and write up 
Report to inform further therapy 
Baseline assessments for 
consented residents 
Focus groups for staff in 
intervention homes 
Figure 2 Flow chart for work plan 3.
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will be encouraged to discuss their work with residents
with dementia, their perceptions of residents’ quality of
life, unmet needs and ways to improve these, the poten-
tial benefits of the intervention and their own role in im-
plementation. The aims and content of the specific
interventions will be considered.
The FGs will be repeated at the end of the pilot study
to explore participants’ experiences of the interventions
and any changes in their views. The researcher will pro-
vide a summary of the FG’s first discussion and seek
feedback on interpretation and any changes in views
post intervention. They will be asked to discuss positive
and negative outcomes, obstacles and facilitators in deli-
vering the intervention. Their views on refining the
interventions will be sought. All group discussions will
be audio-recorded and transcribed verbatim.
Intervention fidelity
To monitor intervention fidelity, each therapist will be
required to videotape at least two interventions and/or
planning sessions. In addition, the type and frequency of
interventions will be determined through audit of an
intervention log completed by the therapist; audit of
detailed intervention plans describing each intervention
undertaken; audit of care plans; and a supervision log. In
particular, given that there is a degree of overlap be-
tween the social interaction and pleasant activities inter-
vention and the exercise intervention, it will be
especially important to ensure that the exercise interven-
tion specifically promotes exercise-based activities and
to clearly profile the similarities and differences in these
two intervention packages.
Economic evaluation
The economic evaluation in this pilot study will focus
on the amount of staff time needed and the overall cost
of each intervention, as well as the patterns of service
use for individual residents and the associated costs. It
will do this by collecting information on the current liv-
ing arrangements (including usual place of residence
and other places of residence); followed by questions
about any use the participant may have made of a range
of hospital, community-based and day services (both
health and social care) over a defined retrospective
period. These data on service contacts, staff time and
costs will be examined alongside data on outcomes to
help preparation for the main study later in the WHELD
programme.
Inclusion, exclusion and withdrawal criteria
Home selection: inclusion, exclusion and withdrawal criteria
Eight care homes will represent a convenience sample
(block 1) of local care homes, already known to the
research team, which meet the inclusion and exclusion cri-
teria and have previously expressed a willingness to partici-
pate in research. The other eight care homes will be
identified from all care homes in the research area rated as
‘adequate’ or better on the Care Quality Commission
(CQC) register (block 2). All care homes listed in the CQC
register that meet the study’s inclusion and exclusion cri-
teria will be entered into a study database. Next, this list of
eligible care homes will be randomised and the homes
approached in the order of appearance on the randomised
list. If a care home declines to participate the next care
home on the list will be approached.
Care homes scored adequate or better on the CQC
register will be eligible for inclusion. Care homes in
which 60% or fewer of the residents have dementia, and
care homes receiving special support from a local au-
thority will be excluded.
Participant selection: inclusion, exclusion and withdrawal
criteria
All residents who potentially eligible for evaluation will
be identified by the care home staff. The inclusion cri-
teria will be individuals residing in participating care
homes and meeting the diagnostic criteria for dementia,
a score of 1 or greater on the Clinical Dementia Rating
Scale (CDR) [25], and a score of 4 or greater on the
functional assessment staging (FAST) [26]. Any resident
for whom consent is not obtained will be excluded. In
terms of withdrawal criteria, individual participants
would be able to withdraw from the study evaluation at
any time.
Staff selection: inclusion, exclusion and withdrawal
criteria
All staff working in participating care homes would be po-
tentially eligible to participate in the FGs as part of the
qualitative evaluation. Consent for their participation will
be sought separately. They will be excluded if consent is
not obtained and are able to withdraw from the study at
any time.
Assessment and follow up
Assessments will be made pre-baseline to assess the suit-
ability of the care homes for inclusion, as shown in Table 1.
This process will include assessments to identify the total
number of participants likely to be eligible for screening.
Participants will be screened and consent obtained prior to
baseline evaluation and to randomization of the care
homes. Follow up assessments will be made nine months
after commencement of the intervention.
Data management and analysis
It is planned that anonymous data and all appropriate
documentation will be kept securely for a period of seven
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Domain Purpose How long to
complete
Who completes Pre-
BL
BL Ongoing Post-
int
Measures of home
Number and approximate
proportion of residents with
dementia
Demographic Eligibility 1 hour - records
search and
informant interview
Researcher Y Y
Rating on CQC criteria Demographic Eligibility 15 mins - records
search
Researcher Y Y
Measures of individual
Demographics Demographic Demographics 10 mins - records
search and
informant interview
Researcher Y Y
Functional assessment
staging (FAST) [26]
Diagnostic criteria Eligibility 15 mins trial
assessments and
informant interview
Researcher Y Y
CDR [25] Diagnostic criteria Eligibility 15 mins - trial
assessments and
informant interview
Researcher Y
Antipsychotic use (number
and proportion of people
and dose)
Medication use Quantitative 5 mins per resident
- records search
and drug chart
Researcher Y Y
Primary
outcome
Use of other psychotropic
drugs (No. and proportion
of people and dose)
Medication use Quantitative 5 mins per resident
- records search
and drug chart
Researcher Y Y
Secondary
outcome
Cohen-Mansfield agitation
inventory (CMAI) [27]
Agitation Quantitative 10 mins Researcher with
staff
YY
Primary
outcome
Neuropsychiatric inventory -
nursing home version (NPI-
NH) [28]
Other behavioural and neuro-
psychiatric symptoms including
apathy and psychosis
Quantitative 20 mins Researcher with
staff
YY
Secondary
outcome
Cornell depression scale
[29]
Mood Quantitative 10-15 mins Researcher with
staff and residents
YY
Secondary
outcome
Rating anxiety in dementia
(RAID) [30]
Mood Quantitative 10-15 mins each Researcher with
staff and residents
YY
Secondary
outcome
Camberwell assessment of
need in the elderly (CANE)
[31]
Unmet needs Quantitative 30 mins each Researcher with
staff and residents
YY
Secondary
outcome
Assessment of QoL for
people with dementia
(DEMQOL) [32]
Quality of life (QoL) Quantitative 20 mins each Researcher with
staff and
separately with
residents
YY
Secondary
Outcome
QoL in Alzheimer’s disease
(QoL-AD) [33]
Quality of life Quantitative 5-10 mins Researcher with
staff and
separately with
residents
YY
Secondary
Outcome
Quality of interaction
schedule (QUIS,
observational tool) [34]
Quality of interactions between
staff and residents
Quantitative 2 hours
observation per
home
Researcher Y Y
Secondary
Outcome
Falls record Falls Quantitative 5 mins Care staff Y
Secondary
outcome
Case examples Skills and attitude development Qualitative Researcher Y
Implementation process Qualitative Researcher Y
Staff time Economic Researcher Y
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cussion with relevant Ethics Committees.
Quantitative data management
Administrative databases will be held at the study centre.
All participants and care homes will be identified by a
unique study number; this number will be used to tag all
research data sent outside the study centre, for example to
North Wales Organisation for Randomised Trials in Health
Clinical Trials Unit (NWORTH CTU). Quantitative
research data will be entered via a web interface to the
MACRO
TM research databases held at NWORTH. Primary
data management will be conducted by the research team
in the study centre, and the secondary cleaning and prepar-
ation of the data for analysis will be conducted by
NWORTH.
Quantitative data analysis
With the exception of the quality of interaction schedule
(QUIS) observational study, which is conducted at a group
level, all outcome data will be collected at an individual
level for the individual participants. Outcome measures for
pilot evaluation will be assessed at baseline and nine
months and are listed in Table 1. All the outcome measures
collected will be described and reported using appropriate
descriptive statistics, tabular and graphical techniques.
Particular note will be taken of baseline SDs and overall ef-
fect sizes. These data will be used to inform power calcula-
tions for Work Plan 5 (WP5). The change from baseline in
the PCC group will quantified and fully described.
The CONSORT diagram information will be assessed
to identify potential differences in dropout rates and
other data quality issues in order to inform the design of
WP5. A more detailed statistical analysis plan will be
drawn up prior to analysing the data, which will be
approved by the programme steering group and the Data
Monitoring and Ethics committee.
The analysis of outcomes will involve a multilevel analysis
of variance (ANOVA) model for the 2×2 ×2 factorial
design with two replications among the care homes and
participants, clustered within each care home. The three
factors being examined are the presence or not of anti-
psychotic review, of social interaction and of exercise. The
two replications refer to the two lists of care homes, those
previously known and those not known to the investigators.
Means with 95% confidence intervals will be quoted and a
5% significance level will be reported. As this is a
hypotheses-generating pilot study, no adjustment will be
made for multiple comparisons.
Qualitative data management and analysis
All group discussions will be audio-recorded and tran-
scribed verbatim. A systematic analysis procedure, based
upon the principles of grounded theory, will be used to
generate increased understanding of the implications of
care staff attitudes for the implementation of the interven-
tions. The aim of the analysis will be to increase the level of
abstraction of themes from descriptive to interpretive. The
procedure will involve at least two members of the research
team independently indexing sections of the transcriptions
with descriptive codes. These codes will then be organised
into more abstract categories and the links between these
categories identified. The categories generated in the last
stage (theoretical coding) are expressed as hypotheses or
propositions. Constant comparison and negative case ana-
lysis will be applied to the data from different settings to
increase understanding of the processes underlying
response to the interventions. Findings of the qualitative
study will contribute to the optimization of the interven-
tions, the training and the implementation approaches in
t h el a r g e rR C T ,W P 5 .T h eq u a l i t a t i v es t u d ym a ya l s os h e d
more light on specific outcomes and mediators (working
mechanisms) of the interventions, as described previously.
These considerations will need to be taken into account in
the planned RCT.
Regulatory and management issues
Ethics approval
The study was approved by Oxfordshire Research Ethics
Service Committee C (REC number 11/SC/0066). Site-
specific assessment (SSA) was obtained from each partici-
pating NHS Hospital Trust. The study will be conducted in
accordance with the recommendations for physicians
involved in research on human subjects adopted by the
18th World Medical Assembly, Helsinki 1964 and later
revisions.
Consent
Potential participants will be identified by the managers of
the participating care homes. They will seek permission
from the resident and/or their personal consultee to be sent
information by the research team. If permission is granted,
the research team will discuss the study in further detail
with the resident and/or personal consultee via telephone
Table 1 Outcome and study eligibility measures (Continued)
Economic measures
Client service receipt
inventory [35]
Information on service contacts Economic 45 mins Researcher Y
Administrative records Cost of intervention Economic Researcher Y
CQC, Care Quality Commission; QUIS, quality of interaction schedule; BL, Baseline; Pre-int, Pre-intervention; Y, Yes.
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the individual. In addition, the relevant study information
sheet will either be given to or sent to the resident and/or
personal consultee. With the written consent of the partici-
pant, or the advice of the consultee, researchers will request
information about diagnosis direct from GP surgeries.
The Mental Capacity Act research guidance on consent
will be followed. All of the participants will be people with
dementia living in the participating care homes so it is likely
that a minority of potential participants will have capacity
to provide informed consent. Initial conversations will take
place with a potential personal consultee. If the personal
consultee feels that it is appropriate for the person to take
part but feels they potentially have the capacity to make
their own decision, an assessment of capacity will be under-
taken by a study clinician. If the individual does have cap-
acity, a simplified written information sheet will be
provided to the individual and the study will be explained
to the person by a member of the research team with ap-
propriate training and skills, where possible with the next
of kin also present. If the individual wishes to take part,
written consent will be taken. In addition, as a measure of
good practice, signed assent will be requested from the con-
sultee. For individuals who do not have capacity, an appro-
priate member of the research team will discuss the study
in further detail with a consultee of the potential study par-
ticipant through telephone conversations or a meeting, de-
pending on their preference. No individuals will participate
in the evaluation without signed, written consent from
themselves or a signed declaration from their consultee.
All participants are free to withdraw at any time from the
study without giving reasons and without prejudicing fur-
ther treatment. For people who lose capacity, the consultee
would be approached and the issue of ongoing participation
would be discussed. If the consultee wants the person to
continue to participate, the consultee will be asked to sign
the declaration form. Ongoing participation would only
require the completion of the nine-month outcome assess-
ment. For the qualitative study, separate consents will be
taken for staff members wishing to participate in the study
FGs.
Confidentiality
The chief investigator will preserve the confidentiality of
participants taking part in the study and is registered under
the Data Protection Act (DPA, 1998). The research will
follow DPA guidance. Only members of the research team
will have access to the original data, which will be stored in
a locked filing cabinet. Participants’ personal details will be
stored separately from the original data, and will be kept in
a separate file on a password-protected computer at the
study centre. Each participant will be assigned an identifica-
tion code, which will be used in all data storage files; these
will not contain names or any other means of personal
identification. All personal details will be deleted on com-
pletion of the study.
Trial status
The trial started recruitment in May 2011 and will
complete follow up assessments in 2012. Results will be
reported in 2013.
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